Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1975)	12/22/2003 8:19:18 AM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Millennium Initiates Phase I Clinical Trial of MLN3897 Monday December 22, 8:07 am ET -- First product candidate to enter clinical trials from Aventis collaboration -- # CAMBRIDGE, Mass., Dec. 22 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced the initiation of a phase I clinical trial of MLN3897, the first compound to enter clinical trials from its inflammation collaboration with Aventis Pharmaceuticals, Inc. MLN3897 (Aventis' compound code: AVE-9897), an orally-administered small molecule, is designed to block CCR1, a chemokine receptor found on the surface of various cells in the immune system which is believed to play a role in a number of inflammatory conditions, including rheumatoid arthritis, multiple sclerosis and psoriasis. The primary objectives of this double-blind, placebo- controlled, single dose-escalation study are to evaluate the safety, tolerability, pharmacokinetic and to obtain preliminary information on receptor binding properties of the compound. "Advancing MLN3897 into the clinic represents real progress from the Millennium-Aventis collaboration and we believe it is a precursor to further success," said Robert I. Tepper, M.D., president of research and development at Millennium. "We believe that our expertise and knowledge of this critical cell trafficking pathway is going to enable us to develop breakthrough medicines for areas of significant unmet medical need, such as these chronic inflammatory conditions." CCR1 is believed to play an important role in the MIP-1a/RANTES/CCR1 chemokine pathway. This receptor signals monocytes and T cells to travel to sites of injury, such as arthritic joints, as part of the inflammatory process. It is also believed that an antagonism of CCR1 could potentially offer new therapeutic approaches in a variety of inflammatory and autoimmune indications. For more information about this and other clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at (800) 589-9005. The Millennium-Aventis Collaboration Millennium and Aventis Pharmaceuticals, Inc. formed an alliance in June 2000 focused on identifying drug targets and developing new therapies for inflammatory diseases. Scientists are collaborating on discovery, development and commercialization of small molecule drugs for the treatment of inflammation-based conditions such as rheumatoid arthritis, asthma and multiple sclerosis. The companies are sharing inflammation discovery pipeline assets, jointly developing new technologies and sharing costs equally.